FN Archimer Export Format
PT J
TI Therapeutic effect of fucoidan-stimulated endothelial colony-forming cells in peripheral ischemia
BT 
AF SARLON, G.
   ZEMANI, F.
   DAVID, L.
   VAN HUYEN, J. -P. Duong
   DIZIER, B.
   GRELAC, F.
   COLLIEC-JOUAULT, Sylvia
   GALY-FAUROUX, Isabelle
   BRUNEVAL, P.
   FISCHER, Anne-Marie
   EMMERICH, J.
   BOISSON-VIDAL, Catherine
AS 1:1,2;2:3;3:4;4:5;5:6,7;6:6,7;7:9;8:6,7;9:5;10:6,7,8;11:6,7,10;12:6,7;
FF 1:;2:;3:;4:;5:;6:;7:PDG-RBE-BRM-BMM;8:;9:;10:;11:;12:;
C1 INSERM, UMRS608, Marseille, France.
   Hop La Timone, AP HM, Dept Vasc Med & Surg, Marseille, France.
   Univ Mohamed Boudiaf, Dept Mol Genet, Oran, Algeria.
   Therapol, Paris, France.
   Hop Europeen Georges Pompidou, AP HP, Dept Pathol, Paris, France.
   INSERM, UMRS765, Paris, France.
   Univ Paris 05, Sorbonne Paris Cite, France.
   Hop Europeen Georges Pompidou, Dept Haematol, AP HP, Paris, France.
   IFREMER, Nantes, France.
   Hop Europeen Georges Pompidou, AP HP, Dept Vasc Med, Paris, France.
C2 INSERM, FRANCE
   HOP LA TIMONE, FRANCE
   UNIV MOHAMED BOUDIAF, ALGERIA
   THERAPOL, FRANCE
   HOP EUROPEEN GEORGES POMPIDOU, FRANCE
   INSERM, FRANCE
   UNIV PARIS 05, FRANCE
   HOP EUROPEEN GEORGES POMPIDOU, FRANCE
   IFREMER, FRANCE
   HOP EUROPEEN GEORGES POMPIDOU, FRANCE
SI NANTES
SE PDG-RBE-BRM-BMM
IN WOS Ifremer jusqu'en 2018
   copubli-france
   copubli-univ-france
   copubli-int-hors-europe
   copubli-sud
IF 6.08
TC 29
UR https://archimer.ifremer.fr/doc/00065/17616/18204.pdf
LA English
DT Article
DE ;angiogenesis;endothelial colony-forming cells;fucoidan;ischemia;revascularization
AB . Background: Fucoidan, an antithrombotic polysaccharide, can induce endothelial colony-forming cells (ECFC) to adopt an angiogenic phenotype in vitro. Objectives: We evaluated the effect of fucoidan on vasculogenesis induced by ECFC in vivo. Methods: We used a murine hindlimb ischemia model to probe the synergic role of fucoidan-treatment and ECFC infusion during tissue repair. Results: We found that exposure of ECFC to fucoidan prior to their intravenous injection improved residual muscle blood flow and increased collateral vessel formation. Necrosis of ischemic tissue was significantly reduced on day 14, to 12.1% of the gastronecmius cross-sectional surface area compared with 40.1% in animals injected with untreated-ECFC. ECFC stimulation with fucoidan caused a rapid increase in cell adhesion to activated endothelium in flow conditions, and enhanced transendothelial extravasation. Fucoidan-stimulated ECFC were resistant to shear stresses of up to 21 dyn cm-2. Direct binding assays showed strong interaction of fucoidan with displaceable binding sites on the ECFC membrane. Bolus intramuscular administration of fucoidan 1 day after surgery reduces rhabdomyolysis. Mice injected with fucoidan (15 mg kg-1) had significantly lower mean serum creatine phosphokinase (CPK) activity than control animals. This CPK reduction was correlated with muscle preservation against necrosis (P < 0.001). Conclusions: Fucoidan greatly increases ECFC-mediated angiogenesis in vivo. Its angiogenic effect would be due in part to its transportation to the ischemic site and its release after displacement by proteoglycans present in the extracellular matrix. The use of ECFC and fucoidan together, will be an efficient angiogenesis strategy to provide therapeutic neovascularization.
PY 2012
PD JAN
SO Journal Of Thrombosis And Haemostasis
SN 1538-7933
PU Wiley-blackwell
VL 10
IS 1
UT 000298843500006
BP 38
EP 48
DI 10.1111/j.1538-7836.2011.04554.x
ID 17616
ER

EF